Prevalence of tuberculosis and its impact on mortality among HIV infected patients in Chile;Tuberculosis en individuos con infección por VIH en Chile: Estudio de prevalencia e impacto sobre mortalidad

Revista Medica de Chile

Volumn 136, Issue 5, 2008, Pages 578-586

  Villarroel Del Pino, Luis ^a,c   Rabagliati, Ricardo ^a   Balcells, M Elvira ^a   Karzulovic, Lorena ^b   Pérez, Carlos ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

HIV; Prevalence; Tuberculosis

Indexed keywords

ADULT; AIDS RELATED COMPLEX; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILE; CLINICAL TRIAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PREVALENCE; RETROSPECTIVE STUDY; TUBERCULOSIS; VIRUS LOAD;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CD4 LYMPHOCYTE COUNT; CHILE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MULTIVARIATE ANALYSIS; PREVALENCE; RETROSPECTIVE STUDIES; TUBERCULOSIS; VIRAL LOAD;

EID: 48849091405     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. World Health Organisation, Geneva. Global Tuberculosis database. In: http://www.who.int/mediacentre/factsheets/fs104. (Consultado el 20 de agosto de 2007).
2. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO); AIDS Epidemic Update: Special Report on HIV/AIDS, december 2006
3. CORBETT EL, WATT CJ, WALKER N, MAHER D, WILLIAMS BG, RAVIGLIONE MC ET AL. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-21.
4. Ministerio de Salud. División de Prevención y Control de Enfermedades. Programa Nacional de Control de la Tuberculosis. Manual de Organización y Normas Técnicas, 2005. Disponible en URL: http://www.minsal.cl/ici/manual_organizacion_normas_tecnicas_control_tbc.pdf. (Consultado el 20 de agosto de 2007).
5. Ministerio de Salud. Departamento de Epidemiología. Evolución del VIH-SIDA, Chile 1986-2005, octubre 2006.
6. WOLFF M, BELTRÁN C, VÁSQUEZ P, AYALA M, VALENZUELA M, BERRÍOS G, ARREDONDO A. The Chilean AIDS Cohort A model for evaluating the impact of an expanded access program to antiretroviral therapy in a middle-income country - Organization and preliminary results. J Acquir Immune Defic Syndr 2005; 40: 551-7.
7. KISH L. (1965). Survey Sampling. John Wiley and Sons, New York, USA.
8. nd Ed. John Wiley and Sons, New York, USA.
9. HOSMER DW, LEMESHOW S. Applied logistic regression. Wiley 2000.
10. R Development Core Team (2006). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.Rproject.org. (Consultado el 20 de agosto de 2007).
11. GIRARDI E, RAVIGLIONE MC, ANTONUCCI G, GODFREY FAUSSET P, IPPOLITO G. Impact of the HIV epidemic on the spread of other diseases: the case of tuberculosis. AIDS 2000; 14 (Suppl 3): S47-56
12. Center for Disease Control and Prevention. Treatment of tuberculosis. MMWR 2003; 52(RR-11).
13. GRAM NM, NELSON KE, SOLOMON L, BONDS M, RIZZO RT, SCAVOTTO J ET AL. Prevalence of tuberculin positivity and skin test anergy in HIV-1 seropositive and seronegative intravenous drug users. JAMA 1992; 267: 369-73.
14. TISSOT F, ZANETTI G, FRANCIOLI P, ZELLEWEGER JP, ZYSSET F. Influence of Bacille Calmette-Guérin vaccination on size of tuberculina skin test reaction: To what size? Clin Infect Dis 2005; 40: 211-7.
15. HORSBURGH CR JR. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350: 2060-7
16. WILKINSON D, SQUIRE SB, GARNER P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomized placebo controlled trials. BMJ 1998; 317: 625-9.
17. HAVILR DV, BARNES PF. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1999; 340: 367-73.
18. SCHOLTEN JN, DRIVER CR, MUNSIFF SS, KAYE K, RUBINO MA, GOUREVITCH MN ET AL. Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. Clin Infect Dis 2003; 37: 1686-92.
19. WOLDEHANNA S, VOLMINK J. Treatment of latent tuberculosis infection in HIV infected persons (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Son, Ltd.
20. RIVERO A, LÓPEZ-CORTÉS L, CASTILLO R, LOZANO F, GARCÍA MA, DIEZ F ET AL. A randomized trial of three regimos to prevent tuberculosis in HIV-infected patients with anergy. Enferm Infecc Microbiol Clin 2003; 21: 287-92.
21. FISK T, HON H-M, LENNOX J, REYN CF, HORSBURGH JR CR. Detection of latent tuberculosis among HIV-infected patients after initiation of Highly active antiretroviral therapy. AIDS 2003; 17: 1102-4.
22. ANTONUCCI G, GIRARDI E, RAVIGLIONE M, VANACORE P, ANGARANO G, CHIRIANO A ET AL. Guidelines of tuberculosis preventive therapy for HIV-infected persons: a prospective, multicentre study. Eur Respir J 2001; 18: 369-75.
23. GORDIN FM, COHN DL, MATTS JP, CHAISSON RE, O'BRIEN RJ ET AL. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? Clin Infect Dis 2004; 39: 561-5.
24. BALCELLS ME, THOMAS SL, GODFREY-FAUSSETT P, GRANT AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006; 12: 744-51.
25. WHALEN C, HORSBURGH CR, HOM D, LAHART C, SIMBERKOFF M, ELLNER J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995; 151: 129-35.